Neurocrine Biosciences, Inc. (NBIX) Stock Price & Analysis
Neurocrine Biosciences, Inc. (NBIX) closed at USD 143.29 on Thursday, October 22, 2026, up 1.40% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 141.31; the Oct 22, 2026 session ranged USD 140.75–143.83 on volume of 1,244,530 shares. Market capitalization is $14.57B, with a 52-week range of USD 122.14–186.12 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:17 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NBIX.md
Key facts (NBIX)
- Last four reported quarters (through Jun 30, 2026): revenue $3.37B, net income $706M (20.9% margin), free cash flow $870M (SEC filings).
- Valuation: P/E 20.6x (avg 41.7x at the last 3 fiscal year-ends).
- 1 of 80 tracked superinvestors hold NBIX (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (29 analysts), mean target USD 206.22 (range 150–253).
- Total return with dividends: 1Y -0.3% vs S&P 500 +14.9%; 5Y +38.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD 2.76, revenue estimate $1.05B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NBIX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B | $3.37B |
| Gross profit | $1.12B | $1.47B | $1.85B | $2.32B | $2.81B | — |
| Operating income | $103M | $249M | $251M | $571M | $619M | $795M |
| Net income | $89.6M | $155M | $250M | $341M | $479M | $706M |
| EPS (diluted) | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 | — |
| Free cash flow | $233M | $323M | $362M | $557M | $749M | $870M |
| Gross margin | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% | — |
| Operating margin | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% | 23.6% |
| Net margin | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% | 20.9% |
| Revenue growth | +8.4% | +31.3% | +26.8% | +24.8% | +21.4% | — |
| Cash + short-term investments | $711M | $989M | $1.03B | $1.08B | $1.48B | — |
| Total debt | $335M | $0K | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NBIX)
P/E 20.6x · P/S 4.3x · P/FCF 16.7x · P/B 3.9x · FCF yield 5.98% · Earnings yield 4.84% · Buyback yield (TTM) 0.45%
P/E at fiscal year-ends: Dec 2025 30.4x, Dec 2024 41.5x, Dec 2023 53.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (NBIX)
1 of 80 tracked investors hold NBIX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Dodge & Cox Funds | Dodge & Cox | 0.49% | $941M | Added +2.3% |
Analysts (NBIX)
Consensus Buy (mean 2.00 on a 1–5 scale), 29 analysts; mean target USD 206.22 (low 150, high 253).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | Needham | Reiterated | Buy | $204 |
| 2026-10-12 | BMO Capital | Target lowered | Market Perform | $164 → $150 |
| 2026-09-29 | UBS | Target lowered | Buy | $231 → $214 |
| 2026-09-11 | Morgan Stanley | Target raised | Equal-Weight | $182 → $183 |
| 2026-09-08 | RBC Capital | Reiterated | Outperform | $198 |
| 2026-09-03 | Citigroup | Target raised | Buy | $249 → $253 |
| 2026-08-13 | Morgan Stanley | Target lowered | Equal-Weight | $196 → $182 |
| 2026-08-03 | Canaccord Genuity | Target raised | Buy | $200 → $210 |
| 2026-08-03 | Truist Securities | Target raised | Buy | $200 → $213 |
| 2026-08-03 | Wedbush | Target raised | Outperform | $185 → $194 |
| 2026-07-31 | Citigroup | Target raised | Buy | $246 → $249 |
| 2026-07-31 | RBC Capital | Target raised | Outperform | $195 → $198 |
Total return (dividends reinvested) (NBIX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -0.3% | +38.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -0.3% | +6.7% |
| Volatility (annualized) | 34.0% | 31.6% |
| Max drawdown | -27.1% (Jul 2026→Oct 2026) | -40.7% (Jul 2024→Apr 2025) |
NBIX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Net product sales | $954.3M | 99.5% | +39.9% |
| Collaboration revenues | $4.7M | 0.5% | -14.5% |
| Total revenue | $959.0M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
NBIX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Voyager Therapeutics, Inc. (VYGR) | “For 2024 compared to 2023, the decrease primarily reflected the payment of a $143.9 million upfront fee in 2023 pursuant to the expansion of our collaboration with Voyager.” |
| Partner | AbbVie (ABBV) | “Our portfolio of products includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc. In addition, we have a diversified portfolio of multiple compounds in mid- to late-phase develop…” |
| Partner | Nxera Pharma UK | “In 2021, we entered into a collaboration and license agreement with Nxera (formerly Sosei Heptares) to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, which we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Nxera retains the rights to develop, manufacture, and commercialize all co…” |
| Partner | TAKEDA PHARMACEUTICAL CO LTD (TAK) | “In 2020, we entered into an exclusive license agreement with Takeda (the 2020 Takeda Agreement), pursuant to which we acquired the exclusive rights to develop and commercialize certain early to mid-stage psychiatry compounds, including luvadaxistat, NBI-1070770, osavampator (NBI-1065845), NBI-1065846, and three non-clinical stage compounds.” |
| Partner | Tanabe Pharma | “We collaborate with TPC for the commercialization of DYSVAL in Japan and for the continued development and commercialization of valbenazine for movement disorders in other select Asian markets.” |
| Partner | Xenon Pharmaceuticals Inc. (XENE) | “In 2019, we entered into a collaboration and license agreement with Xenon to identify, research, and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize.” |
| Partner | Sanofi (SNY) | “In 2014, we entered into a license agreement with Sanofi, pursuant to which we acquired the global rights to develop and commercialize certain corticotropin-releasing factor type 1 (CRF-1) receptor antagonists, including crinecerfont.” |
| Partner | Sentia Medical Sciences | “This program represents the first biologic (peptide) to emerge from our internal discovery collaboration (with Sentia Medical Sciences, Inc.) on novel peptide CRF receptor antagonists, highlighting our expansion into biologics to complement our small-molecule portfolio.” |
| Partner | Mitsubishi Tanabe Pharma | “Cost of revenues primarily consists of third-party manufacturing, transportation, freight, and indirect overhead costs for the manufacture and distribution of INGREZZA and CRENESSITY drug product sold, royalties on net product sales of CRENESSITY, amortization of intangible assets, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Tanabe Pharma Corporation (…” |
Quoted from the company's 10-K filed Feb 11, 2026.
Companies that name NBIX in their SEC reports
| Relationship to NBIX | Company | Filing | Sentence |
|---|---|---|---|
| partner | Lexeo Therapeutics, Inc. (LXEO) | 10-K Mar 30, 2026 | “With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…” |
| partner | Maze Therapeutics, Inc. (MAZE) | 10-K Mar 25, 2026 | “License revenue recognized in 2024 also included amounts related to the exclusive license agreement with Trace Neuroscience, Inc., or Trace, pursuant to which we received an upfront payment of $15.0 million in exchange for the transfer of the license, know-how, and materials related to the research, development, manufacture and commercialization of a discovery research program targeting UNC13A for the treatment of…” |
| partner | Voyager Therapeutics, Inc. (VYGR) | 10-K Mar 9, 2026 | “Two of these programs are in collaboration with Neurocrine: a frataxin (FXN) gene therapy program for FA, which we refer to as the FA Program, and a glucosylceramidase beta 1, or GBA1, gene therapy program that will focus on Gaucher and PD, which we refer to as the GBA1 Program.” |
| partner | Xenon Pharmaceuticals Inc. (XENE) | 10-K Feb 26, 2026 | “In December 2019, we entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy.” |
NBIX customer concentration
In the period ended Jun 30, 2026, 3 direct customers each accounted for at least 10% (34%, 28%, 26%) of revenue, per the company's 10-Q filed Jul 31, 2026. The company does not name them.
NBIX company outlook (results filed Jul 30, 2026)
- “Results reflected double-digit prescription volume growth in TRx and record NRx driven by strong patient demand. • INGREZZA full year 2026 guidance was increased from a range of $2.7 billion to $2.8 billion up to $2.825 billion to $2.875 billion. • CRENESSITY second-quarter 2026 net product sales were $184 million, driven by strong patient demand with approximately 80% rei”
Analysts expect $1.05B for the current quarter, 62.0% below the midpoint of the company's guidance ($2.75B).
Quoted word-for-word from the SEC 8-K results press release.
NBIX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.76 | $2.73 | +1.3% | $1.05B | 17 |
| Next quarter (ends Dec 2026) | $2.84 | $2.73 | +4.2% | $1.09B | 14 |
| Current fiscal year (ends Dec 2026) | $10.27 | $9.95 | +3.2% | $3.90B | 17 |
| Next fiscal year (ends Dec 2027) | $11.97 | $12.66 | -5.4% | $4.56B | 15 |
NBIX options: expected move
Options price a move of about ±10.4% (±$14.85) by Nov 20, 2026, which includes earnings on Nov 2, 2026. Over the last 8 reports the stock moved ±8.8% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 45.7% | ±10.4% |
| Dec 18, 2026 | 56 | 41.6% | ±13.2% |
| Jan 15, 2027 | 84 | 37.6% | ±14.5% |
| Feb 19, 2027 | 119 | 37.6% | ±17.3% |
| Mar 19, 2027 | 147 | 36.4% | ±18.6% |
| May 21, 2027 | 210 | 38.6% | ±23.5% |
| Jun 17, 2027 | 237 | 38.0% | ±24.5% |
| Jul 16, 2027 | 266 | 38.8% | ±26.5% |
30-day implied volatility 42.8% vs 30% realized over the last 30 trading days. Put/call ratio (volume) 0.11. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:17 UTC)
| Price | USD 143.29 |
|---|---|
| Change | ▲ 1.40% (up) |
| Previous Close | USD 141.31 |
| Open | USD 141.62 |
| Day Range | USD 140.75 – 143.83 |
| 52-Week Range | USD 122.14 – 186.12 |
| Volume | 1,244,530 shares |
| Market Cap | $14.57B |
| Exchange | NMS |
Technical Analysis (NBIX)
Nexqual's technical model rates NBIX "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:17 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.19 (neutral) |
| vs SMA50 | Below (USD 147.6) |
| MACD | -2.31 (negative) |
Analyst Ratings (NBIX)
Wall Street analysts rate NBIX "Buy" based on 29 analysts, with a mean price target of USD 206.22 (range USD 150–253), per Nexqual as of October 23, 2026 at 09:17 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 29 |
| Mean Target | USD 206.22 |
| High Target | USD 253 |
| Low Target | USD 150 |
| Buy / Hold / Sell | 25 / 4 / 0 |
Earnings (NBIX)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD 2.76 |
| Revenue Estimate | $1.05B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.85 vs est 1.96 ▲ beat |
| 2026-03-31 | USD 1.94 vs est 1.7 ▲ beat |
| 2025-12-31 | USD 1.88 vs est 2.3 ▼ miss |
| 2025-09-30 | USD 2.17 vs est 2.07 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:17 UTC.
Financials & Fundamentals (NBIX)
| Total Revenue | $3.37B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +39.50% |
| Gross Margin | +64.48% |
| Operating Margin | +22.19% |
| Profit Margin | +20.91% |
| ROE | +22.09% |
| Debt / Equity | 0.12 |
| Current Ratio | 1.87 |
| Total Cash | $389.80M |
| Total Debt | $461.60M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $870.40M (25.8% of revenue) |
Source: Nexqual, October 23, 2026 at 09:17 UTC.
Financial Health Score (NBIX)
Nexqual rates Neurocrine Biosciences, Inc.'s overall financial health "Strong" across five dimensions, as of October 23, 2026 at 09:17 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 64%, operating 22% (last 12 months) |
| Balance Sheet | Strong — $390M cash vs $462M debt |
| Cash Flow | Strong — FCF $870M (last 4 quarters to Jun 2026, SEC), 26% margin |
| Efficiency | Strong — ROE 22%, ROA 11.7% |
Ownership (NBIX)
| Insider Ownership | +1.06% |
|---|---|
| Institutional Ownership | +103.66% |
| Shares Outstanding | 101.65M |
| Float | 100.35M |
| Short % of Float | +7.48% |
Source: Nexqual, October 23, 2026 at 09:17 UTC.
Leadership (NBIX)
Neurocrine Biosciences, Inc. is led by Kyle W. Gano, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:17 UTC.
| President, CEO & Director | Kyle W. Gano |
|---|---|
| Chief Financial Officer | Matthew C. Abernethy |
| Chief Scientific Officer | Jude Onyia |
| Senior Vice President of Finance & Accounting | Aaron Vosburgh |
| Vice President of Investor Relations | Todd Tushla |
Major Backers & Investors (NBIX)
Notable institutional backers of Neurocrine Biosciences, Inc. include JPMorgan, Dodge & Cox Inc., AQR Capital Management, LLC, according to Nexqual as of October 23, 2026 at 09:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 6.29% |
| Dodge & Cox Inc. | 5.49% |
| AQR Capital Management, LLC | 3.76% |
| Renaissance Technologies | 2.3% |
| Two Sigma Investments, LP | 2.04% |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.49% |
| Vanguard Group | 9.36% |
| State Street | 4.31% |
| Geode Capital | 2.1% |
Source: Nexqual, October 23, 2026 at 09:17 UTC.
From Neurocrine Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product's safety and effectiveness after commercialization.
- By harnessing both novel validated mechanisms and our proprietary platforms, we aim to launch, on average, approximately one new medicine every two years, driving long-term value for patients and shareholders.
- We believe our outsourced manufacturing strategy enables us to direct our financial resources to maximize our commercial opportunities with INGREZZA and CRENESSITY, invest in our internal research and development programs, and expand our clinical pipeline through business development opportunities.
- Underpinning all our programs is a reinvigorated research and discovery engine that we have built to be both innovative and efficient.
Partnerships
- Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc.
Legal & Regulatory Risks (Item 1A, quoted)
- Our clinical trials may be delayed for safety or other reasons, or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.
- We are subject to ongoing obligations and continued regulatory review for INGREZZA and CRENESSITY. Additionally, our product candidates, if approved, could be subject to labeling and other post-marketing requirements and restrictions.
- Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations.
- Compliance with changing laws, regulations and standards relating to various aspects of our business, including corporate governance, workforce initiatives and public disclosure, may result in additional expenses and failure to comply with such laws, regulations and standards could adversely affect our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELAN | Elanco Animal Health Incorporat | USD 22.69 | ▲ 0.62% |
| RDY | Dr. Reddy's Laboratories Ltd | USD 13.23 | ▲ 0.3% |
| VTRS | Viatris Inc. | USD 18.48 | ▲ 0.16% |
| UTHR | United Therapeutics Corporation | USD 584.79 | ▲ 3.78% |
| ALKS | Alkermes plc | USD 44.18 | ▲ 1.61% |
| AMRX | Amneal Pharmaceuticals, Inc. | USD 20.48 | ▲ 1.39% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:17 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt